Advertisement

Topics

GTC Biotherapeutics Company Profile

22:54 EDT 21st September 2017 | BioPortfolio

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins using transgenic animal technology. ATryn®, recombinant human antithrombin, is the first transgenically produced therapeutic protein approved anywhere in the world, having recently been approved by the European Commission (EMEA) for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiency. ATryn® was approved for hereditary antithrombin deficiency in the United States (FDA) in February 2009, and remains the only recombinant form of the molecule available for clinical use. ATryn® is produced in the milk of goats using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant proteins and monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases. GTC has active development and commercialization relationships with Lundbeck Inc. and LFB Paris.

Location

175 Crossing Blvd.
Framingham
Massachusetts
01702
United States of America

Contact

Phone: (508) 620-9700
Fax: (508) 370-3797


News Articles [169 Associated News Articles listed on BioPortfolio]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies t...

Pfizer starts work on Missouri biotherapeutics R&D hub

Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Iovance Biotherapeutics appoints Timothy Morris CFO

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced the appointment of Timothy E. Morris as Chie...

Pierre Fabre Acquires Immunotherapies from Igenica Biotherapeutics

NewsPierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology.

Agilis Biotherapeutics, Gene Therapy Research Institution partner

Agilis Biotherapeutics, a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution (GTR...

Biotech Aeglea BioTherapeutics nets $11.7mm through FOPO

Aeglea BioTherapeutics Inc. (enzyme-based therapeutics for rare diseases and cancer) netted $11.7mm through a follow-on public offering of 3mm common shares at $4.10. The company will use the offerin...

Pierre Fabre to buy Igenica Biotherapeutics’ assets for treating cancer patients

French private pharmaceutical group Pierre Fabre has signed a new definitive purchase agreement to acquire several assets from US biotechnology company Igenica Biotherapeutics.

Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Tuesday, September 5th 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline o...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

TILT Biotherapeutics.

Peptide dendrons as thermal stability amplifiers for IgG1 monoclonal antibody biotherapeutics.

Biotherapeutics such as monoclonal antibodies (mAbs) have a major share of the pharmaceutical industry for treatment of life-threatening chronic diseases such as cancer, skin ailments and immune disor...

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.

Today, the assessment of immunogenicity is integral in nonclinical and clinical testing of new biotherapeutics and biosimilars. A key component in the risk-based evaluation of immunogenicity involves ...

To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes.

Strategies aimed at modulating the gut microbiota by using live microbes range from single strains (probiotics or live biotherapeutics) to whole non-defined fecal transplants. Although often clinicall...

Using transgenic plants and modified plant viruses for the development of treatments for human diseases.

Production of proteins in plants for human health applications has become an attractive strategy attributed by their potentials for low-cost production, increased safety due to the lack of human or an...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [93 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

Talecris Biotherapeutics, Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...

More Information about "GTC Biotherapeutics" on BioPortfolio

We have published hundreds of GTC Biotherapeutics news stories on BioPortfolio along with dozens of GTC Biotherapeutics Clinical Trials and PubMed Articles about GTC Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GTC Biotherapeutics Companies in our database. You can also find out about relevant GTC Biotherapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...


Corporate Database Quicklinks



Searches Linking to this Company Record